CDCA5

Across TCGA pan-cancer cohorts, CDCA5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDCA5 data layer compared with 31 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CDCA5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDCA5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and GBM are the cancer types where CDCA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.895	0.267	.004	19	view →
LUAD	DFS	Quartile	II,III,IV	0.925	0.423	.004	12	view →
GBM	DFS	Median	All	0.645	0.324	.014	3	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.702	.016	2	view →
CCRCC	DFS	Median	II,III,IV	0.391	1.000	.033	2	view →
PDAC	DFS	Median	II,III,IV	0.728	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDCA5–HNSC (DFS)

Open the HNSC breakdown →